AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9851957 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic exercise training
Number of subjects: 20
Study 9851957 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 7988260 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP (cyclophosphamide, doxorubicin, cisplatin) chemotherapy plus radiation therapy as preoperative or neoadjuvant therapy
Number of subjects: 39
Study 2691239 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support diet (50 kcal/kg bodyweight/d and 1.5 g protein/kg bodyweight/d)
Number of subjects: 36
Study 2691239 — intervention group
Group type: COMPARATOR
Intervention: Standard diet prescribed by attending physician
Number of subjects: 36
Study 30060100 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 30
Study 30060100 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 30
Study 28159118 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led psycho-education intervention for childbirth fear
Number of subjects: 339
Study 28159118 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 339
Study 25363863 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to temptation with self-regulation endorsement for four consecutive days.
Number of subjects: 0
Study 25363863 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated temptation strength in addition to exposure to temptation.
Number of subjects: 0
Study 23866813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyprinol/Omega XL (PCSO-524)
Number of subjects: 150
Study 23866813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 21929600 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sublingual immunotherapy (SLIT)
Number of subjects: 80
Study 21929600 — intervention group
Group type: COMPARATOR
Intervention: Coseasonal sublingual immunotherapy (SLIT)
Number of subjects: 80
Study 19673328 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-formulated Xingchang Decoction (XCD)
Number of subjects: 118
Study 19673328 — intervention group
Group type: COMPARATOR
Intervention: Mosapride (control)
Number of subjects: 118
Study 19673328 — intervention group
Group type: EXPERIMENTAL
Intervention: XCD
Number of subjects: 118
Study 16721465 — intervention group
Group type: EXPERIMENTAL
Intervention: Delton sealant
Number of subjects: 56
Study 16721465 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Flow sealant
Number of subjects: 56
Study 16721465 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract Flow sealant
Number of subjects: 56
Study 16721465 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer sealant
Number of subjects: 56
Study 15706659 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg OW
Number of subjects: 1053
Study 15706659 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 35 mg OW
Number of subjects: 1053
Study 11714186 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone and mail interventions for higher intensity exercise
Number of subjects: 140
Study 11714186 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone and mail interventions for lower intensity exercise
Number of subjects: 140
Study 11714186 — intervention group
Group type: COMPARATOR
Intervention: Predominantly mail for higher intensity exercise
Number of subjects: 140
Study 11714186 — intervention group
Group type: COMPARATOR
Intervention: Telephone and mail for lower intensity exercise
Number of subjects: 140
Study 9129791 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpathogenic Escherichia coli strain Nissle 1917 (E. coli DSM 6601, Mutaflor)
Number of subjects: 27
Study 9129791 — intervention group
Group type: COMPARATOR
Intervention: Placebo suspension (1 ml of phosphate‐buffered saline)
Number of subjects: 27
Study 8912742 — intervention group
Group type: EXPERIMENTAL
Intervention: Maneuver 1 (rapid inspiration without an end‐inspiratory pause)
Number of subjects: 41
Study 8912742 — intervention group
Group type: COMPARATOR
Intervention: Maneuver 2 (slow inspiration with an end‐inspiratory pause of approximately 5 s)
Number of subjects: 41
Study 8912742 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol administration
Number of subjects: 41
Study 8912742 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing air and after equilibration with 80% helium in oxygen
Number of subjects: 41
Study 2273683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 6
Study 2273683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7008048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 20
Study 7008048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31783907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii™Fit for 30 min/day for 8 weeks
Number of subjects: 36
Study 26939828 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioptron light therapy + cryotherapy
Number of subjects: 50
Study 26939828 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 50
Study 25194951 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 25
Study 25194951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 24656950 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 17
Study 24656950 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 17
Study 22745657 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-skills training plus parental training
Number of subjects: 56
Study 22745657 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 56
Study 20422289 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention program
Number of subjects: 4407
Study 17594260 — intervention group
Group type: EXPERIMENTAL
Intervention: VRET
Number of subjects: 26
Study 17594260 — intervention group
Group type: EXPERIMENTAL
Intervention: VRET plus coping self‐statements
Number of subjects: 26
Study 15802770 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride
Number of subjects: 0
Study 15802770 — intervention group
Group type: COMPARATOR
Intervention: Estrogen
Number of subjects: 0
Study 11935507 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite fiber-reinforced dowels (1.00 mm diameter) luted with BIS-GMA resin bonding system
Number of subjects: 40
Study 11935507 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite fiber-reinforced dowels (1.25 mm diameter) luted with BIS-GMA resin bonding system
Number of subjects: 40
Study 11935507 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite fiber-reinforced dowels (1.50 mm diameter) luted with BIS-GMA resin bonding system
Number of subjects: 40
Study 11935507 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel dowels (1.25 mm diameter) luted with zinc phosphate cement
Number of subjects: 40
Study 11692349 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine
Number of subjects: 20
Study 11692349 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% benzocaine
Number of subjects: 20
Study 11692349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lidocaine-tasting)
Number of subjects: 20
Study 11692349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (benzocaine-tasting)
Number of subjects: 20
Study 8784330 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, parent-child autotutorial program (PCAT group)
Number of subjects: 303
Study 8784330 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face counseling session with a registered dietitian (counseling group)
Number of subjects: 303
Study 8784330 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 303
Study 1628636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine
Number of subjects: 0
Study 1628636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 0
Study 1628636 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 6467772 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents received three letters stressing the value of continuous pediatric care
Number of subjects: 445
Study 6467772 — intervention group
Group type: COMPARATOR
Intervention: Control group (no letters received)
Number of subjects: 445
Study 31209191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Na/K citrate plus saline infusion (treatment group)
Number of subjects: 201
Study 31209191 — intervention group
Group type: COMPARATOR
Intervention: Oral water plus saline infusion (placebo group)
Number of subjects: 201
Study 31209191 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN-positive patients in treatment group
Number of subjects: 201
Study 27889832 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 25 mg co-administered with itraconazole 200 mg twice daily (study A)
Number of subjects: 48
Study 27889832 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 25 mg co-administered with fluconazole 400 mg on day 1 then 200 mg/day (study A)
Number of subjects: 48
Study 27889832 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg co-administered with rifampicin 600 mg/day (study B)
Number of subjects: 48
Study 27889832 — intervention group
Group type: COMPARATOR
Intervention: Selumetinib 25 mg alone (study A)
Number of subjects: 48
Study 27889832 — intervention group
Group type: COMPARATOR
Intervention: Selumetinib 75 mg alone (study B)
Number of subjects: 48
Study 27889832 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib co-administered with itraconazole (study A)
Number of subjects: 48
Study 27889832 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib co-administered with rifampicin (study B)
Number of subjects: 48
Study 27889832 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib co-administered with fluconazole (study A)
Number of subjects: 48
Study 25971244 — intervention group
Group type: EXPERIMENTAL
Intervention: PDSAFE (physiotherapist delivered, individually tailored and progressive, home-based programme)
Number of subjects: 600
Study 25971244 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study 23656463 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy supplement diet (Soy Group, SG; n = 72)
Number of subjects: 140
Study 23656463 — intervention group
Group type: COMPARATOR
Intervention: Casein supplement diet (Casein Group, CG; n = 68)
Number of subjects: 140
Study 21895613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvicol
Number of subjects: 132
Study 21895613 — intervention group
Group type: COMPARATOR
Intervention: Conventional colporrhaphy
Number of subjects: 132
Study 19622007 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + colesevelam HCl
Number of subjects: 0
Study 19622007 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl
Number of subjects: 0
Study 19622007 — intervention group
Group type: COMPARATOR
Intervention: Metformin + matching placebo
Number of subjects: 0
Study 19622007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17597499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum extract (2 grams, twice daily for 10 days)
Number of subjects: 16
Study 17597499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17597499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum extract
Number of subjects: 16
Study 15080351 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine solution applied 3 times at 2-month intervals (N = 13)
Number of subjects: 25
Study 15080351 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group, N = 12)
Number of subjects: 25
Study 11159263 — intervention group
Group type: EXPERIMENTAL
Intervention: Sameridine 0.73 mg/kg (S-Large)
Number of subjects: 12
Study 11159263 — intervention group
Group type: EXPERIMENTAL
Intervention: Sameridine 0.15 mg/kg (S-Small)
Number of subjects: 12
Study 11159263 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.10 mg/kg
Number of subjects: 12
Study 11159263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8483018 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 278
Study 8483018 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 278
Study 8483018 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 278
Study 8483018 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting isosorbide dinitrate
Number of subjects: 278
Study 8483018 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 278
Study 8483018 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 278
Study 3710663 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g daily for 3 weeks)
Number of subjects: 0
Study 3710663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29413502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 125 mg subcutaneously (SC)
Number of subjects: 310
Study 29413502 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg orally
Number of subjects: 310
Study 29413502 — intervention group
Group type: COMPARATOR
Intervention: Placebo SC
Number of subjects: 310
Study 26771423 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate (500 mg/d)
Number of subjects: 27
Study 26771423 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Phosphate (500 mg/d)
Number of subjects: 27
Study 26771423 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 27
Study 26771423 — intervention group
Group type: COMPARATOR
Intervention: Washout
Number of subjects: 27
Study 24829497 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 15
Study 24829497 — intervention group
Group type: COMPARATOR
Intervention: BP education (control intervention)
Number of subjects: 15
Study 24829497 — intervention group
Group type: COMPARATOR
Intervention: Controlled breathing (CB)
Number of subjects: 15
Study 23842679 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (without weight loss)
Number of subjects: 0
Study 23842679 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss
Number of subjects: 0
Study 23842679 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training + weight loss
Number of subjects: 0
Study 20592121 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial skin stretch using a robotic device applied lateral to the side of the mouth before movement initiation.
Number of subjects: 0
Study 20592121 — intervention group
Group type: COMPARATOR
Intervention: Control tests without facial skin stretch.
Number of subjects: 0
Study 17922130 — intervention group
Group type: EXPERIMENTAL
Intervention: Triadcortyl (TAC) ointment
Number of subjects: 64
Study 17922130 — intervention group
Group type: COMPARATOR
Intervention: 10% glycerine-ichthammol (GI) solution
Number of subjects: 64
Study 16626752 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 69
Study 16626752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 12773333 — intervention group
Group type: EXPERIMENTAL
Intervention: Servoventilator breathing
Number of subjects: 7
Study 12773333 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 7
Study 11063474 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention children
Number of subjects: 540
Study 11063474 — intervention group
Group type: COMPARATOR
Intervention: Control children
Number of subjects: 540
Study 8669572 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope
Number of subjects: 167
Study 8669572 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 167
Study 1732266 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral total hip replacement
Number of subjects: 72
Study 1732266 — intervention group
Group type: COMPARATOR
Intervention: Bilateral total hip replacement
Number of subjects: 72
Study 3113778 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH infusion (5 micrograms/min)
Number of subjects: 6
Study 3113778 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Ala2-MePhe4-met-enkephalin-0-ol (DAMME) bolus (250 micrograms)
Number of subjects: 6
Study 3113778 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Ala2-MePhe4-met-enkephalin-0-ol (DAMME) bolus (250 micrograms) after TRH infusion
Number of subjects: 6
Study 3113778 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study 3113778 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion with DAMME bolus
Number of subjects: 6
Study 3113778 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH infusion alone
Number of subjects: 6
Study 3113778 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH infusion with DAMME bolus
Number of subjects: 6
Study 31713994 — intervention group
Group type: EXPERIMENTAL
Intervention: Major abdominal surgery (one surgery)
Number of subjects: 10481
Study 31713994 — intervention group
Group type: EXPERIMENTAL
Intervention: Major abdominal surgery (two or more surgeries)
Number of subjects: 10481
Study 31713994 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple surgeries
Number of subjects: 10481
Study 31713994 — intervention group
Group type: EXPERIMENTAL
Intervention: Stoma formation among surgical patients
Number of subjects: 10481
Study 31713994 — intervention group
Group type: EXPERIMENTAL
Intervention: New ostomates
Number of subjects: 10481
Study 31713994 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical controls
Number of subjects: 10481
Study 28605158 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 32
Study 28605158 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 26426277 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 30
Study 26426277 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 24405341 — intervention group
Group type: EXPERIMENTAL
Intervention: High-stress simulated scenario
Number of subjects: 54
Study 24405341 — intervention group
Group type: COMPARATOR
Intervention: Control simulated scenario
Number of subjects: 54
Study 22515556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose, 90 mg twice daily maintenance dose)
Number of subjects: 0
Study 22515556 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-C124910XX (active metabolite)
Number of subjects: 0
Study 22515556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (after 2 weeks of clopidogrel)
Number of subjects: 0
Study 22515556 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (600 mg loading dose, 75 mg once daily maintenance dose)
Number of subjects: 0
Study 21700254 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide (TiNO)
Number of subjects: 302
Study 21700254 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 302
Study 19812099 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathways (CP) for hospital treatment of HF
Number of subjects: 45
Study 19812099 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 45
Study 19812099 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathways (CP)
Number of subjects: 45
Study 16333533 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 J/cm2 (2x)
Number of subjects: 13
Study 16333533 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 J/cm2 (1x and 2x)
Number of subjects: 13
Study 16333533 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 J/cm2 (2x) and 12 J/cm2 (2x)
Number of subjects: 13
Study 16333533 — intervention group
Group type: EXPERIMENTAL
Intervention: 2x treatment
Number of subjects: 13
Study 16333533 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual ablation thickness
Number of subjects: 13
Study 15584467 — intervention group
Group type: COMPARATOR
Intervention: School-based intervention program designed based on the Attitude, Social Influence and Self-Efficacy model (ASE); implemented in 10 intervention schools.
Number of subjects: 0
Study 15584467 — intervention group
Group type: COMPARATOR
Intervention: Guided classroom activities, computer tailored messages for children, activities to be completed at home with the family, and family targeted specific actions.
Number of subjects: 0
Study 11110422 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise training for 2 weeks
Number of subjects: 28
Study 11110422 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 28
Study 11110422 — intervention group
Group type: COMPARATOR
Intervention: Both groups (training and control)
Number of subjects: 28
Study 9352604 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of rhenium-186
Number of subjects: 79
Study 9352604 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of rhenium-186 in combination with triamcinolone hexacetonide
Number of subjects: 79
Study 9352604 — intervention group
Group type: COMPARATOR
Intervention: Injection of triamcinolone hexacetonide alone
Number of subjects: 79
Study 8239200 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin replacement to a level greater than or equal to 3.5 g/dL (AR group)
Number of subjects: 69
Study 8239200 — intervention group
Group type: COMPARATOR
Intervention: No albumin replacement (NR group)
Number of subjects: 69
Study 3884288 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chest physiotherapy
Number of subjects: 20
Study 3884288 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical chest vibration
Number of subjects: 20
Study 28961405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise at 55% HRmax
Number of subjects: 0
Study 28961405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise at 70% HRmax
Number of subjects: 0
Study 28961405 — intervention group
Group type: COMPARATOR
Intervention: No intradialytic exercise (control)
Number of subjects: 0
Study 28961405 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of IDE at 55% vs. 70% HRmax
Number of subjects: 0